Open Accessibility Menu
Clinical Trials

Clinical Trials in West Alabama

Through our clinical trials program, patients who qualify can access other health care alternatives and investigational new drugs long before they are available on the open market. The Manderson Cancer Center jointly conducts clinical research with MD Anderson Cancer Center.

Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center is a National Cancer Institute (NCI) Central Institutional Review Board Signatory Institution. We are also an affiliate member of NRG Oncology which brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon their more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

During the months of January through December 2019, a total of 84 patents were accrued to trials, and the following data were collected:

  • During the months of January through December 2019, a total of 52 patents were accrued to trials.
  • Treatment/Interventional Trials – 3 offsite; 1 onsite
  • Diagnostic Trials – 30 onsite
  • Prevention and Control Research – 18 onsite is a searchable database that provides patients, family members and the public with information about current ongoing clinical research studies.

For any questions or to learn if you qualify for a clinical trial, please contact our Clinical Research Coordinator, Danielle Daniel, by phone at (205) 759-6237 or by email at

Below is a list of clinical trials that are currently offered at Manderson Cancer Center. We have attached the link for each study for ease in finding detailed information regarding these studies.

NRG Oncology

NRG-GU005 - Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer (Principal Investigator – Dr. J. Curtis Tucker, MD)

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Click here for details about this Prostate Cancer clinical trial.

NRG-CC003 - A Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (Principal Investigator - J. Curtis Tucker, MD)

This trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer. Click here for details.

External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease (Principal Investigator – Dr. J. Curtis Tucker, MD)

This phase II trial studies how well systemic therapy with or without local consolidative therapy work in treating patients with solid tumor that has spread to 1 site of other places in the body. Treatment with up-front local consolidative therapy may be better in helping to control the disease. Learn more about this clinical trial here.

Lung Cancer Studies

INSIGHT – An Observational Study Assessing the Clinical Effectiveness of Veristrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (Principal Investigator – Dr. John W. Dubay, MD, PhD)

The primary purpose of this study is to assess the physician’s clinical practice patterns while using Veristrat in subjects with non-small cell lung cancer whose tumors are epidermal growth factor receptor (EGFR) wild-type or EGFR negative. Learn more about this clinical trial here.

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) (Principal Investigator – Dr. John W. Dubay, MD, PhD)

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following standard of care SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. Learn more about this non-small cell lung cell cancer clinical trial here.

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (Principal Investigator – Dr. John W. Dubay, MD, PhD)

The purpose of this study is to observe and collect data for people with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). For further details, click here.